Jorjen, I could not agree more, nothing has changed and if you need further confirmation of the strong backdrop for the business Cambridge Cognition (their only real competitor) put out a very strong trading update yesterday.
I also think a lot of investors came in specifically to play the Aducanumab approval and while that roll out has been well below expectations it changes very little for the Cogstate. In fact the recent Medicare draft ruling, if implemented, may even end up being a positive, as it would require any amyloid lowering treatment to gather (post FDA approval or phase IV ) real world evidence in trials before providing wide payment coverage.
CGS Price at posting:
$1.65 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)